Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition affecting the optic nerve head
Regular check-ins with your prescribing physician are important to evaluate results and decide whether to continue, adjust, or stop
16-18,22 The estimated treatment differences between the semaglutide 2.4 mg and placebo arms ranged from 6.2% (95% CI, 7.3% to 5.2%) in STEP 2 to 14.8% (95% CI, 16.0% to 13.5%) in STEP 4
Reduced liver fat has been seen with Retatrutide 50mg
The patient in our case underwent two full-body FDG-PET-CT scans, the first in the immediate post-operative period and the second at one-year follow-up
Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs